
China's CStone inks deal worth $192.5 M with Istituto Gentili to commercialise cancer drug in Europe
China's CStone inks deal worth $192.5 M with Istituto Gentili to commercialise cancer drug in Europe July 10, 2025 | Thursday | News Gentili will receive exclusive commercialisation rights for sugemalimab in 23 European countries China-based CStone …